个人信息Personal Information
教授
博士生导师
硕士生导师
任职 : 教授
性别:男
毕业院校:九州大学理学部
学位:博士
所在单位:生物工程学院
学科:生物化学与分子生物学. 细胞生物学. 生药学
办公地点:生物楼603
联系方式:邮编:116024 大连市高新区凌工路2号 大连理工大学生物楼603 电话:0411-84706105
电子邮箱:wuhj@dlut.edu.cn
DEC1 regulates breast cancer cell proliferation by stabilizing cyclin E protein and delays the progression of cell cycle S phase
点击次数:
论文类型:期刊论文
发表时间:2015-09-01
发表刊物:CELL DEATH & DISEASE
收录刊物:SCIE、PubMed、Scopus
卷号:6
期号:9
页面范围:e1891
ISSN号:2041-4889
摘要:Breast cancer that is accompanied by a high level of cyclin E expression usually exhibits poor prognosis and clinical outcome. Several factors are known to regulate the level of cyclin E during the cell cycle progression. The transcription factor DEC1 (also known as STRA13 and SHARP2) plays an important role in cell proliferation and apoptosis. Nevertheless, the mechanism of its role in cell proliferation is poorly understood. In this study, using the breast cancer cell lines MCF-7 and T47D, we showed that DEC1 could inhibit the cell cycle progression of breast cancer cells independently of its transcriptional activity. The cell cycle-dependent timing of DEC1 overexpression could affect the progression of the cell cycle through regulating the level of cyclin E protein. DEC1 stabilized cyclin E at the protein level by interacting with cyclin E. Overexpression of DEC1 repressed the interaction between cyclin E and its E3 ligase Fbw7 alpha, consequently reducing the level of polyunbiquitinated cyclin E and increased the accumulation of non-ubiquitinated cyclin E. Furthermore, DEC1 also promoted the nuclear accumulation of Cdk2 and the formation of cyclin E/Cdk2 complex, as well as upregulating the activity of the cyclin E/Cdk2 complex, which inhibited the subsequent association of cyclin A with Cdk2. This had the effect of prolonging the S phase and suppressing the growth of breast cancers in a mouse xenograft model. These events probably constitute the essential steps in DEC1-regulated cell proliferation, thus opening up the possibility of a protein-based molecular strategy for eliminating cancer cells that manifest a high-level expression of cyclin E.